Blog Read the latest perspectives from our team of subject matter experts and others How Incyte Is Advancing Clinical Trial DiversityDiversity in clinical trials is more than just a regulatory requirement—it’s a critical component of equitable healthcare. Ensuring that trial participants reflect the real-world patient population leads to more… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Drug Development Global Impact HCP Volunteers KOL Engagement Patient Representation Provider Data Research Post Industries:Commercialization Global Impact Health Plans & Digital Health Pharmaceutical & Biotechnology Provider Data Research Drug DevelopmentPatient RepresentationThe Post-Pandemic Future of Clinical TrialsIn a post-COVID world, we’re seeing a decade’s worth of reshaping within clinical trials solidify in less than a year. While the life sciences industry was making a slow… Continue reading → Read the article CommercializationDrug DevelopmentPatient RepresentationWhy Diversity Matters for PharmaDiversity matters for pharma because inclusion, trust and equity matter for pharma. When developing therapies and medications, pharmaceutical and life sciences companies are tasked with designing products for a… Continue reading → Read the article KOL EngagementWhy Physicians May Want to Become Key Opinion LeadersDuring drug development, life science companies often turn to healthcare professionals (HCPs) for input, advice and expertise. These HCPs advising companies are generally known as Key Opinion Leaders (KOLs), thought… Continue reading → Read the article KOL EngagementEducating Physicians to Improve the Patient Diagnostic JourneyThe best diagnostic journey for a patient is the shortest. The less time is lost between a patient seeing a healthcare provider for the first time for their symptoms… Continue reading → Read the articleno KOL EngagementDr. Sekar Kathiresan’s Impact on CardiologyScholarly Influence Publications Dr. Kathiresan is a cardiologist and the CEO of Verve Therapeutics, a company that works on gene editing medicine for cardiovascular disease. Additionally, he is… Continue reading → Read the article KOL EngagementThe Term KOL: Keep It or Ditch It?Listening to webinars and reading reports about the latest trends and developments in medical affairs is one of the things we do incessantly at H1 – after all we need… Continue reading → Read the article«‹10111213141516›»
